Kit Malthouse - Alert Sample

Alert Sample

View the Parallel Parliament page for Kit Malthouse

Information between 14th September 2025 - 24th September 2025

Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.

Division Votes
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 85 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 329 Noes - 163
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 81 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 332 Noes - 160
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 82 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 328 Noes - 160
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 83 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 314 Noes - 178
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 85 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 326 Noes - 160
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 81 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 327 Noes - 164
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 82 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 316 Noes - 172
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 85 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 330 Noes - 158
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 83 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 316 Noes - 161
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 82 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 330 Noes - 161
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 83 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 330 Noes - 161
15 Sep 2025 - Employment Rights Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 82 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 318 Noes - 170
16 Sep 2025 - Sentencing Bill - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 72 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 340 Noes - 77
16 Sep 2025 - Sentencing Bill - View Vote Context Kit Malthouse voted Aye - in line with the party majority and against the House One of 73 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 78 Noes - 292
16 Sep 2025 - Child Poverty Strategy (Removal of Two Child Limit) - View Vote Context Kit Malthouse voted No - in line with the party majority and against the House One of 75 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 89 Noes - 79

Kit Malthouse mentioned

Select Committee Documents
Tuesday 16th September 2025 Oral Evidence - DSIT, Office for Life Sciences, and Department of Health and Social Care (DHSC) Science, Innovation and Technology Committee Found: Q36 Kit Malthouse: Who is making the decision about that offer? Is it you?
Tuesday 16th September 2025 Oral Evidence - MSD, ABPI (The Association of the British Pharmaceutical Industry), and AstraZeneca Science, Innovation and Technology Committee Found: meeting Members present: Dame Chi Onwurah (Chair); Emily Darlington; George Freeman; Tom Gordon; Kit Malthouse

Kit Malthouse - Select Committee Information

Calendar
Tuesday 14th October 2025 9 a.m. Science, Innovation and Technology Committee - Oral evidence Subject: Innovation showcase View calendar - Add to calendar

Select Committee Documents
Wednesday 3rd September 2025 Oral Evidence - ARIA, and ARIA Science, Innovation and Technology Committee
Tuesday 16th September 2025 Oral Evidence - DSIT, Office for Life Sciences, and Department of Health and Social Care (DHSC) Science, Innovation and Technology Committee
Tuesday 16th September 2025 Oral Evidence - MSD, ABPI (The Association of the British Pharmaceutical Industry), and AstraZeneca Science, Innovation and Technology Committee

Select Committee Inquiry
2 Oct 2025 Life sciences investment Science, Innovation and Technology Committee (Select) Not accepting submissions With MSD cancelling its £1 billion ongoing manufacturing site in Kings Cross, AstraZeneca pausing its £200 million investment in its Cambridge site, and the latter upgrading its US listing, the Science, Innovation and Technology Committee is launching a call for evidence on UK life sciences competitiveness. This follows an initial emergency session, where it heard from representatives from MSD and AstraZeneca, as well as the ABPI, and from officials and ministers, including Minister for Science, Research and Innovation, Patrick Vallance. The call for written evidence will examine the competitiveness of the UK’s life sciences sector, barriers to innovation for medicines in the UK, issues with pricing uptake and access, and the impact of other countries’ policies.

Select Committee Inquiry

2 Oct 2025
Life sciences investment
Science, Innovation and Technology Committee (Select)
Not accepting submissions

With MSD cancelling its £1 billion ongoing manufacturing site in Kings Cross, AstraZeneca pausing its £200 million investment in its Cambridge site, and the latter upgrading its US listing, the Science, Innovation and Technology Committee is launching a call for evidence on UK life sciences competitiveness.

This follows an initial emergency session, where it heard from representatives from MSD and AstraZeneca, as well as the ABPI, and from officials and ministers, including Minister for Science, Research and Innovation, Patrick Vallance.

The call for written evidence will examine the competitiveness of the UK’s life sciences sector, barriers to innovation for medicines in the UK, issues with pricing uptake and access, and the impact of other countries’ policies.